par Beresniak, Ariel;Medina-Lara, Antonieta;Auray, Jean Paul;De Wever, Alain ;Praet, Jean Claude ;Tarricone, Rosanna;Torbica, Aleksandra;Dupont, D;Lamure, Michel;Duru, G.
Référence PharmacoEconomics, 33, 1, page (61-69)
Publication Publié, 2014-09
Référence PharmacoEconomics, 33, 1, page (61-69)
Publication Publié, 2014-09
Article révisé par les pairs
Résumé : | Quality-adjusted life-years (QALYs) have been used since the 1980s as a standard health outcome measure for conducting cost-utility analyses, which are often inadequately labeled as 'cost-effectiveness analyses'. This synthetic outcome, which combines the quantity of life lived with its quality expressed as a preference score, is currently recommended as reference case by some health technology assessment (HTA) agencies. While critics of the QALY approach have expressed concerns about equity and ethical issues, surprisingly, very few have tested the basic methodological assumptions supporting the QALY equation so as to establish its scientific validity. |